Cell therapy · us
CAR-NK therapy shows early responses in myositis and systemic sclerosis, but durability remains unclear
Nkarta reported preliminary human data for NKX019, with signals of disease improvement in two small patient groups. However, some patients also received other immune therapies, and the overall safety data show that conditioning before cell infusion still carries risks.
For patients with autoimmune diseases who have had limited benefit from existing treatments, eliminating B cells involved in disease may offer another treatment approach. Nkarta announced on November 9 that its experimental CAR-NK cell therapy NKX019 showed preliminary signals of improvement in small groups of patients with myositis and systemic sclerosis. These data begin to address whether the therapy has clinical activity, but are not yet sufficient to establish how long its effects may last.
NKX019 uses natural killer cells from healthy donors, engineered to recognize CD19 on the surface of B cells. The main efficacy data reported came from the Phase 1/2, open-label Ntrust-2 trial, with a data cutoff of September 18, 2026. In the dose group highlighted by the company, patients received 4 billion cells on each of Days 0, 3, and 7 following lymphodepleting conditioning, for a total of 12 billion cells.
Among the 6 patients with myositis who received this dose and had at least three months of follow-up, 5 achieved a moderate or major response. Responses were assessed using the Total Improvement Score (TIS), which combines disease measures including muscle strength and patient and physician assessments. A score of at least 40 indicates a moderate response, and a score of at least 60 indicates a major response. This is a signal of improvement across multiple dimensions and cannot be directly interpreted as disease remission or a cure.
The effects of other treatments must also be considered when assessing one patient's subsequent response. According to the company's 8-K filing, this patient had achieved a moderate response by Day 37. Starting around Day 50, a community rheumatologist administered steroids and intravenous immunoglobulin outside the trial protocol, and the patient achieved a major response by Day 120. The extent to which the later improvement was attributable to NKX019 cannot be isolated. Two other patients who received lower doses had early responses that were not sustained and subsequently received additional immunomodulatory drugs because of increased disease activity.
In systemic sclerosis, the 4-billion-cell dose group included 9 patients, of whom 7 had reached Day 90 of follow-up at the data cutoff. Of these, 6 met the revised Composite Response Index rCRISS-25 threshold, and 5 met the rCRISS-50 threshold. This index combines skin, lung function, physical function, and overall assessments. In the same patients, the median reduction in the modified Rodnan skin score was 15 points. However, meeting a composite index threshold does not mean that every organ improved equally, nor does it establish that existing fibrosis has been reversed.
Safety must be considered together with conditioning. In pooled data from 40 patients across five autoimmune indications, no deaths, discontinuations due to adverse events, cytokine release syndrome, or graft-versus-host disease were reported. However, the investor presentation listed Grade 3 or higher treatment-emergent adverse events in 14 patients, serious adverse events in 7, and serious infections in 2. The company attributed the main hematologic adverse events to lymphodepleting conditioning. Thus, the absence of specific cell therapy toxicities does not mean that the full treatment regimen is free of major risks.
The trial is also adjusting the dosing schedule. The presentation showed that NKX019 exposure increased with dose, while patients' own T cells began to recover before the Day 7 infusion. Based on these findings, the company shortened the schedule to Days 0, 2, and 4 and plans to evaluate 6 billion cells per infusion. The current data cannot answer whether the new schedule will improve efficacy. The existing results come from a small, open-label trial with limited follow-up and no direct comparison with other therapies. Larger samples and longer follow-up are still needed for confirmation.
### Background context
Nkarta has expanded NKX019 administration to outpatient settings at community trial sites, aiming to make off-the-shelf cell therapy more accessible. This update adds preliminary efficacy findings and more complete safety information. Whether short-term disease improvement can translate into a durable treatment that can be reliably delivered in community settings remains a question for further development.